What question did this study set out to answer?

This research aims to standardize decision-making in cases of de novo oligometastatic breast cancer through a dedicated clinic.

May 30, 2026

Dedicated multidisciplinary oligometastatic breast cancer clinic (OMBCC) as a platform for standardized decision-making and real-world evidence generation.

Key Points

This research aims to standardize decision-making in cases of de novo oligometastatic breast cancer through a dedicated clinic.
A central monthly clinic was established, led by a multidisciplinary team of breast cancer specialists.
Patients with de novo metastatic breast cancer with 5 or fewer metastases were referred for evaluation.
Prospective data collection included clinicopathological characteristics and metabolic responses via serial PET scans.
The clinic evaluated 14 patients since its launch in July 2025, demonstrating consistent operation and multidisciplinary attendance.
Recommendations included 71% for surgery, 36% for consolidative radiation, and 36% for metastasis-directed therapy.
The setup supports coordinated decision-making across specialties, improving patient management.

Abstract

e13614 Background: Management of de novo oligometastatic breast cancer remains controversial, where randomized trials are limited by feasibility, heterogeneity, and patient selection. While aggressive locoregional and metastasis-directed therapy may benefit select patients, variability in practice and lack of standardized multidisciplinary evaluation limit consistent care. To address this gap, our centre established a dedicated multidisciplinary OMBCC with the intent to standardize decision-making, optimize patient selection, and serve as a platform for prospective data collection and clinical trial facilitation. Methods: The OMBCC is a central monthly clinic led by a multidisciplinary team of breast cancer specialists, including surgical, medical, and radiation oncologists. Referral criteria include patients with de novo MBC with < / = 5 metastases. Each case undergoes multidisciplinary review with consensus recommendations for investigations, optimal systemic therapy, locoregional management, metastasis-directed therapy, and potential enrolment on relevant clinical trials. Prospective data collection includes clinicopathological characteristics, imaging, and metabolic response to therapy with serial PET scans. Results: The OMBCC clinic was launched in July 2025 with 14 patients evaluated to date. Clinic feasibility was demonstrated through consistent operation, multidisciplinary attendance, and standardized documentation of recommendations. Key patient demographics, disease characteristics and management recommendations are summarized in Table 1. The clinic provides centralized expert consensus to enable coordinated and consistent decision-making across disciplines. Ongoing data collection will support evaluation of treatment patterns, changes in management, and enrollment into clinical trials. Conclusions: Establishment of a dedicated multidisciplinary OMBCC is feasible and provides a structured platform for standardized decision-making in a clinically controversial area where randomized evidence is limited. This care delivery model supports consistent evaluation, screening for clinical trials, and prospective real-world data generation to optimize management for carefully selected patients with de novo oligometastatic breast cancer, with the intent to improve outcomes. Demographic and clinical characteristics, and treatment recommendations. Age at Diagnosis, median (range) 41 (32-57) HR+, HER2-, n (%) 7 (50%) Node positive, n (%) 12 (86%) Number of metastases, median (range) 2 (1-6) On 1 st line systemic therapy, n (%) 8 (57%) Recommended surgery for locoregional disease, n (%) 10 (71%) Recommend consolidative RT after locoregional surgery, n (%) 5 (36%) Recommend primary RT to locoregional disease, n (%) 1 (7%) Recommend metastasis-directed therapy with SABR, n (%) 5 (36%)

Ask AI

Helpful

Bookmark